21:20 , Nov 22, 2017 |  BC Extra  |  Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
23:28 , Jul 14, 2014 |  BC Extra  |  Politics & Policy

India caps prices of 50 CV and diabetes drugs

India's National Pharmaceutical Pricing Authority ( NPPA) Januvia sitagliptin from Merck & Co. Inc. (NYSE:MRK) and Volibo voglibose from Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). The only non-insulin diabetes drugs included on India's list of...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

SciClone, Sanofi sales and marketing update

SciClone announced that it and Sanofi agreed to group together and renew until Dec. 31 deals in which Sanofi granted SciClone exclusive commercialization rights to four of its products in China. The products are ...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

Micardis telmisartan regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-0 against approval of Micardis telmisartan from Boehringer to prevent cardiovascular events in patients at high risk of such events. The panel did vote 5-2 in favor...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter...
00:02 , Jul 30, 2009 |  BC Extra  |  Company News

Panel rebuffs Micardis for CV events in high risk patients

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-0 against approval of Micardis telmisartan from Boehringer Ingelheim GmbH (Ingelheim, Germany) to prevent cardiovascular events in patients at high risk of such events. The panel did...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Clinical News

Polycap: Phase II data

Data from the double-blind, Indian Phase II TIPS trial showed that in 2,053 patients ages 45-80 and with 1 risk factor for cardiovascular disease, Polycap was non-inferior to thiazide, atenolol, ramipril or combinations of the...
08:00 , Dec 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease ...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

Micardis telmisartan: Additional Phase IV data

Additional data from the double-blind, international Phase IV ONTARGET trial showed that 80 mg of Micardis was as efficacious, and significantly better tolerated, than 10 mg ramipril in a subgroup of 3,137 Asian-Pacific patients at...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Clinical News

Micardis telmisartan: Phase IV data

In the double-blind, international Phase IV ONTARGET trial in 25,620 high-risk cardiovascular patients, the 56-month rate of cardiovascular death, myocardial infarction, stroke and hospitalization for CHF for telmisartan was noninferior to ramipril (16.7% vs. 16.5%)....